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Abstract
Background A better knowledge of methicillin-resistant
Staphylococcus aureus (MRSA) persistence in hospitalised
patients may impact on speciﬁc prevention strategies. We
have investigated the persistence of MRSA-carriage in
patients admitted and re-admitted to a university hospital.
Patients and methods Between January 2002 and October
2005 all MRSA-positive patients admitted to the university
hospital of Hannover Medical School were assessed at ﬁrst
admission and all subsequent re-admissions. Patients re-
admitted at least once were analysed for the persistence or
loss of MRSA. The association of possible factors inﬂu-
encing the persistence of MRSA colonisation or infection
(age group, gender, decolonisation therapy during ﬁrst
hospital stay due to MRSA positivity and colonisation of
different anatomical sites) was analysed using univariate,
multivariate and time-dependent analyses.
Results A total of 1,032 patients who had tested positive
at least once for MRSA were admitted to our hospital
during the study period, accounting for 2,038 admissions.
Of these patients, 403 (39.1%) were admitted more than
once (from two times to 21 times), and 238 (59.1%) of the
re-admitted patients remained MRSA positive during all
subsequent admissions. Fifty-ﬁve (13.6%) patients tested
MRSA negative at their last admission, and 61 (15.1%)
tested MRSA negative at at least two consecutive admis-
sions. In 27 (6.7%) patients, the MRSA status differed
more than once between subsequent admissions. Overall,
the half-life time (HLT) of MRSA persistence was
549 days, with the duration of persistence dependent on the
colonisation of different anatomical sites (HLT only
wounds 117 days; HLT mouth, throat, bronchial secretions
627 days; HLT nose, wounds and other body sites
801 days; p\0.01) and was prolonged if more than one
body site was MRSA-positive (HR 2.18, 95% conﬁdence
interval 1.52–3.15).
Conclusion A detailed knowledge of the dynamics of the
loss of MRSA infection could result in a reduction of the
incidence of MRSA in the future. Multiple anatomical site
carriage of MRSA appeared to predict a prolonged per-
sistence in our cohort of patients re-admitted to a university
hospital.
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Introduction
The spread of methicillin-resistant Staphylococcus aureus
(MRSA) in North America and Europe has increased
morbidity and mortality among patients admitted to hos-
pitals as well as the costs of hospital stays over the past
30 years [1–10]. As MRSA is known to be transmitted
mostly by health-care contacts [7, 11, 12], it is important to
determine whether initially MRSA-positive patients can
lose their MRSA colonisation and to which extent and
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addressing the persistence of MRSA in patients hospita-
lised at least once describe half-life persistence times
between 225 and 360 days, depending on the patient cohort
investigated and the different decolonisation treatment
applied [13–16]. Knowledge of the duration of MRSA
persistence should impact on recommendations to ﬂag
patients who have once tested positive for MRSA in terms
of testing them at re-admissions, but to date no recom-
mendation exists regarding how long a patient should be
ﬂagged as an infection-control risk [17, 18]. In the study
reported here, we investigated all patients admitted to a
university hospital who had tested positive for MRSA at
least once during slightly less than a 4-year period. Our aim
was to determine MRSA persistence of the ﬁrst and sub-
sequent hospital stays and the time dependency of the loss
of MRSA. We also analysed whether a topical decoloni-
sation therapy during the ﬁrst admission favoured or hin-
dered the loss of MRSA and to what extent the MRSA loss
was dependent on colonised anatomical sites.
Methods
Study design and setting
A cohort study was performed from January 2002 to
October 2005 that included all detected MRSA-positive
patients (either by clinical specimen or by screening cul-
ture) admitted to the university hospital of the Hannover
Medical School (MHH) during the study period. The MHH
hospital has 1,400 beds, with nearly 45,000 patient
admissions per year, accounting for 400,000 patient-days.
Prospective surveillance of MRSA-positive patients
Diagnosis of a ﬁrst positive microbiological result for
MSRA at any anatomical site resulted in the patient being
entered in our surveillance system, and all patient data
being entered into a database that serves as an alert system
in the case of subsequent re-admissions [19]. For every
patient with a MRSA-positive test result, additional swabs
of the nose, throat and wounds if present were recom-
mended to estimate the extent of MRSA colonisation. An
infection control nurse visited each patient, recommending
a decolonisation therapy [mupirocin nasal ointment 3 times
per day to both nares for 5 days, daily body and throat
washings for 5 days with disinfectants containing octeni-
dine (octenisept) or chlorhexidine (skinsept mucosa)]. The
physician in charge decided if a decolonisation therapy
should be initiated, and if initiated, the topical decoloni-
sation therapy was recorded in the database. A systemic
decolonisation therapy was not recommended. MRSA
targeting antibiotic therapy was only initiated if infections
were present.
Deﬁnition of a negative MRSA status
We deﬁned an initially MRSA-positive patient as ‘‘MRSA
negative’’ if three specimens taken at the anatomical sites
that had originally tested MRSA positive, tested MRSA
‘‘negative’’ on at least 3 subsequent days. In addition, nares
were tested for MRSA. Negative results were only accep-
ted if MRSA susceptible antibiotics were stopped at least
2 days before the ﬁrst swab was taken.
Microbiological diagnostic of MRSA
All clinical specimens were cultured according to routine
microbiological diagnostic procedures on 5% sheep blood
agar (BBL Microbiology Systems, Becton–Dickinson,
Heidelberg, Germany) and mannitol salt agar (own pro-
duction). The antibiotic susceptibility of S. aureus isolates
was measured by broth micro dilution with the MICRO-
NAUT
TM system (Merlin Diagnostika GmbH, Hensel,
Germany).
From July 2004 to October 2005, only screening swabs
were cultured directly onto a selective culture medium
(MRSA ID-Agar
TM; bioMerieux, Marcy l’Etoile, France).
Susceptiblity interpretations were made according to
breakpoints in accordance with the Deutsche Ingenieur
Norm (DIN) 58940-4.
Isolates were conﬁrmed using an agglutination test for
penicillin-binding protein 2a (PBP’2 Latex Agglutiniation
kit; bioMe ´rieux).
MRSA status of re-admitted patients
All MRSA-positive discharged patients had to be
re-examined upon re-admission at all of the initially
MRSA-positive anatomical sites and the nose and throat. If
these were missed (42 cases, 10.4%), the patient was
regarded as ‘‘MRSA-positive’’. In contrast to Robiczek
et al. [14], we preferred to overestimate rather than
underestimate the MRSA persistence in order to maximise
the safety of possible recommendations regarding how long
MRSA-positive patients should be ﬂagged.
Observation period of initially MRSA-positive patients
For every MRSA-positive patient that had been entered
into the database, all subsequent admissions during the
study period were included in our study. The microbio-
logical database was retrospectively checked for MRSA-
positive as well as for any MRSA-negative specimens for
all patients. The overall observation period of each patient
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ﬁrst admission during which the ﬁrst positive MRSA
result was detected from the date of discharge of the last
hospital admission. Patients who had once tested ‘‘MRSA
negative’’ were not screened at re-admission for reasons
of their initial MRSA positivity, although they could be
screened as a result of belonging to a high risk group.
Patients who were screened could be detected as MRSA
positive once again based on laboratory testing of clinical
specimens.
Determination of the anatomical MRSA colonisation
site of the patient
We grouped all patients into the following distinct colo-
nisation groups to enable an analysis of MRSA-site
dependent persistence, with each different anatomical site
that tested MRSA positive considered independent of the
time point when the detection was made: (1) only nares; (2)
only wounds; (3) nares and other anatomical sites but no
wounds; (4) throat, mouth, tracheal secretion, bronchial
secretion or bronchoalveolar lavage (BAL) without nares;
(5) nares and other anatomical sites including wounds; (6)
other anatomical sites, including urinary tract and ano-
genital region without nares and without wounds; (7)
wounds and other anatomical sites without nares; (8) any
other anatomical sites and combinations which are not
already described above.
Determination of the MRSA status of a patient
at the end of a hospital stay
The MRSA status of a patient was determined as ‘‘posi-
tive’’ in any case in which no three negative samples of an
initially MRSA-positive anatomical site or nares could be
obtained on at least three subsequent days—under the
condition that no MRSA-susceptible antibiotics had been
given.
Deﬁnition of the patient cohorts for the MRSA
persistence analysis (univariate analysis, Kaplan–Meier
survival analysis, Cox proportional hazards models)
All patients who had tested MRSA positive at least once
and had been re-admitted at least once during the study
period were included in our study. The ﬁrst day of the
colonisation time was determined as either the admission
date (if the patient had positive MRSA results from another
laboratory) or the date of the ﬁrst MRSA-positive speci-
men. The last day was deﬁned as the day on which the ﬁrst
of three MRSA-negative specimens was diagnosed
according to our deﬁnition of a MRSA-negative status in
the case of patients losing the MRSA infection and the date
of the last hospital discharge during the study period for
patients remaining MRSA-positive.
For the Kaplan–Meier analysis and Cox proportional
hazards models, all patients who changed MRSA status
between admissions at least twice (e.g. positive–negative–
positive pattern during subsequent admissions) were
excluded from the analysis. We elected to perform a time-
dependent analysis even though the data were interval
censored (the exact day of MRSA loss between two hos-
pital stays can not be determined). The resulting overesti-
mation of MRSA persistence is adequate for deﬁning safe
intervals for how long MRSA-positive patients should be
ﬂagged after discharge.
The Cox proportional hazard models analysis for the
time until loss was performed using the variables ‘‘age
B65 years’’ and ‘‘topical decolonisation therapy’’ as
dichotome variables and ‘‘anatomical sites of colonisation’’
as parametric variables. All variables were included in the
ﬁnal model.
Statistical analysis
Fisher’s exact test or chi-square tests, log rank sum tests,
Kaplan–Meier survival analysis and Cox proportional
hazards models analysis were performed as appropriate
using SPSS software ver. 15.0 (SPSS, Chicago, IL).
P values\0.05 were regarded as signiﬁcant.
Results
A total of 1,032 patients who had tested positive at least
once for MRSA were admitted to our hospital during the
study period, accounting for 2,038 admissions. Of these,
403 patients were admitted more than once (range: 2–21
times), accounting for 1,409 admissions. Microbial speci-
mens adequate for MRSA detection were available for 84%
of all admissions (2,038); the remaining 16% were either
re-admissions or ﬁrst admissions (20 patients) for which
the MRSA have been tested ‘‘positive’’ by external labo-
ratories. In the ﬁrst case, the original MRSA status for the
patient remained unchanged (i.e. was the same as their
former hospital admission). Per admission, a median of
nine (4: 25% percentile, 21: 75% percentile) microbial
cultures of a median of three (2: 25% percentile; 5: 75%
percentile) different body sites were performed. Table 1
shows how many patients remained MRSA positive, how
many lost their MRSA-positive status and how many
switched between a MRSA-positive and MRSA-negative
status between different admissions as well as the fre-
quency of MRSA-‘‘positive’’ tested anatomical sites, the
initiation of a decolonisation therapy at the ﬁrst MRSA-
positive admission and colonisation of either one or more
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MRSA negative were screened again at least on of their re-
admissions. Fifty-ﬁve MRSA-negative patients were not
re-admitted, and screening cultures during re-admission
were missing for 22 patients.
The over-all half-life time (HLT) of MRSA persistence
was 566 days for a patient who had been re-admitted at
least once. To detect a potential bias by different re-
admission frequencies between the MRSA-persistence and
MRSA-loss group, we tested whether these groups differed
by re-admission frequency. However, no signiﬁcant dif-
ference was found (data not shown).
Patients with a MRSA colonisation at anatomical sites
‘‘nares and others excluding wounds’’ had about a threefold
increased duration of MRSA persistence (HLT 630 days)
compared to patients colonised at the anatomical site ‘‘only
nares’’ (HLT 197 days) or ‘‘only wounds’’ (HLT 123 days)
(Fig. 1). Patients colonised at ‘‘throat, mouth, tracheal
secretion, bronchial secretion or BAL without nares’’ (HLT
576 days) and those colonised at ‘‘other anatomical sites
including urinary tract and ano-genital region without nares
or wounds’’ (HLT 387 days) showed an increased MRSA
persistence.
Both the univariate and Kaplan–Meier analyses
revealed that gender was not a signiﬁcant risk factor for
prolonged MRSA persistence (HLT 566 days for males,
420 days for females; p = 0.90). Patients in the age
groups B65 and [65 years, respectively, did not differ in
MRSA persistence (HLT 554 vs. 549 days, respectively;
p = 0.18).
Patients colonised at only one anatomical site had a
signiﬁcantly shorter MRSA persistence than those
Table 1 Study cohort including
all patients who had tested
MRSA positive at least once
and had been re-admitted at
least once (Patients’
characteristics/anatomical
colonisation sites/topical
decolonisation)
SD Standard deviation, MRSA
methicillin-resistant
Staphylococcus aureus, BAL
bronchoalveolar lavage
a Data from patients available
for anatomical site
determination, comprising
results of screening cultures for
nares, throats and wounds and
cultures of clinical specimens
b Only patients with available
information for decolonisation
were included (n = 394)
Characteristics Number (%; unless otherwise
stated)
Number of patients 403
Male 257
Age[65 years 121
Age (years): (mean ± SD, median, range; 25-, 75-percentiles) 52.9 ± 19.7, 57.0, 0–92; 41.0,
68.0
Duration of observation period (days): (mean ± SD, median,
range; and 25-, 75- percentiles)
301.2 ± 271.5, 210, 1–1325; 94,
435
MRSA status of patients at the time of discharge of their last observed
admission during the study period
At all subsequent discharges MRSA-positive 238 (59.1%)
Only at the last observed re-admission MRSA-negative 55 (13.6%)
At the last observed at least two re-admissions MRSA-negative 61 (15.1%)
At one admission MRSA-negative followed by re-admission(s)
with no conﬁrmation of MRSA negativity
22 (5.4%)
At subsequent admissions switching MRSA status (positive–
negative–positive, positive–negative–positive–negative–positive)
27 (6.7%)
Patients with MRSA colonisations at anatomical site groups
a
Only nares 48 (11.95%)
Nares and other anatomical sites but no wounds 114 (28.3%)
Nares and other anatomical sites including wounds 90 (22.3%)
Throat, mouth, tracheal secretion, bronchial secretion or BAL
without nares
38 (9.4%)
Only wounds 21 (5.2%)
Wounds and other anatomical sites without nares 38 (9.4%)
Other anatomical sites including urinary tract and ano-genital
region without nares and without wounds
34 (8.4%)
Any other anatomical sites which are not already described
above
19 (6.7%)
Unknown colonisation site 1 (0.2%)
Single anatomical colonisation site 84 (20.9%)
Multiple anatomical colonisation site 318 (79.1%)
Topical decolonisation therapy initiated during the ﬁrst MRSA-positive
admission
b
153 (38.8%)
366 F. Mattner et al.colonised at multiple anatomical sites [see Fig. 2; hazard
ratio (HR) 2.18, 95% conﬁdence interval (CI) 1.52–3.15;
p (v
2-test)\0.01].
The effect of a topical decolonisation therapy during the
ﬁrst admission was tested after the exclusion of all patients
with alternating MRSA status. The univariate analysis
revealed a signiﬁcant effect of topical decolonisation
therapy for the ﬁrst admission [odds ratio (OR) 4.01, 95%
CI 1.69–9.48, p\0.01]. In contrast, the time-dependent
analysis (Kaplan–Meier and Cox proportional hazards
models) revealed that the effect of decolonisation therapy
during the ﬁrst MRSA-positive admission was not signiﬁ-
cant (HLT 413 vs. 734 days; p = 0.20).
Multivariate data analysis (Cox proportional hazards
models) including the variables ‘‘anatomical site of
colonisation’’, ‘‘age at ﬁrst stay (B65/[65 years)’’ and
‘‘decolonisation during the ﬁrst stay’’ revealed a signiﬁcant
association of the MRSA persistence to colonisation of
different anatomical sites (Table 2).
Discussion
The admittance of MRSA-colonised patients to hospitals
represent a major challenge to healthcare providers
charged with ensuring the safety of patient care in hos-
pitals [20]. As MRSA is easily transmitted in hospitals,
expensive isolation precautions are recommended to pre-
vent further nosocomial spread [18]. The aim of our study
was to determine the probability that patients once hos-
pitalised for MRSA and then re-admitted would lose the
MRSA infection again over the long term. To this end,
we followed our MRSA cohort over a number of years
and observed MRSA colonisation or loss from re-admis-
sion to re-admission.
Almost 40% of our MRSA-positive patients were
re-admitted to our hospital, underlining that only an auto-
matedalertsystemenablesthereliablerecognitionofalready
known MRSA-positive patients and, thus, the immediate
initiation of MRSA-transmission prevention measures.
Our investigation revealed that one-fourth of our cohort
lost the MRSA infection after about 4 months; after about
18 months, half of the cohort was MRSA-free. Due to their
decision to underestimate MRSA persistence rather than
overestimate it (as we did), the durations recently reported
by Robiczek et al. were shorter than those reported here
[14]. In contrast to a number of other studies, our study
cohort comprised only patients treated in and re-admitted
to a university hospital, which implies that the patients
were possibly sicker than those in other studies (Table 3).
In addition, we did not perform any follow-up during
ambulatory care. Again, the resulting selection and detec-
tion bias of our study cohort also result in an
Fig. 1 Methicillin-resistant Staphylococcus aureus (MRSA) persis-
tence in patients re-admitted at least once according to MRSA colo-
nisations at different anatomical sites. (For this analysis, 27 (6.7%)
patients with at least two changes in MRSA status between hospital
stays were excluded). p (v
2-test)\0.01
Fig. 2 MRSA persistence according to colonisation at single or at
multiple anatomical sites [28 (6.9%) patients with unknown anatom-
ical site colonisation were excluded]. Hazard ratio 2.18, 95%
conﬁdence interval 1.52–3.15, p\0.01. Thick line Colonisation at
a single anatomical site, dotted line colonisation at multiple anatom-
ical sites
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MRSA persistence among out study cohort demonstrates
that formerly hospitalised MRSA-positive patients may
also impact on patient care facilities for out-patients.
Therefore, a diagnostic, therapeutic and transmission pre-
ventive management programme for these patients is
warranted in the context of ambulatory care. The ﬁrst step
is the implementation of MRSA networks [21]. On the
other hand, long-term observation periods for MRSA holds
some interest because a consequent prevention of MRSA
transmission in hospitals would result in a natural reduction
of MRSA-positive patients over the years if no additional
cases were to occur. Our data also suggest that MRSA-
positive patients should not only be entered in an alert
system but also redrawn when the MRSA infection is lost.
This implies that an MRSA alert database should be
updated on a regular basis. Of course, conﬁdence in the
method of just how to assess that the MRSA is ‘‘lost’’ is
always limited. However, in our study, we required three
negative microbiological results for the initial MRSA-
positive anatomical sites, nares, throat and any wounds in
the absence of antibiotic treatment effective against MRSA
and on at least three different days. All patients from whom
we obtained less than three negative specimens of the
respective colonisation sites were considered to be MRSA
‘‘positive’’ even if the materials obtained were MRSA-
negative. Thus, we are rather sure that the cohort that
became MRSA negative was at most underestimated and
that the cohort with MRSA persistence might have been
overestimated. In addition, we observed that we had only a
rather small patient cohort of about 6% who changed their
MRSA status between different admissions at least twice,
which is consistent with data published by Vriens et al.
[16]. We had insufﬁcient data to determine whether our
MRSA-negative patients would be recolonised after a
longer period during ambulatory care. This important
question should be addressed in future studies using a study
design with an active controlled screening protocol.
The effects of a decolonisation treatment that have been
reported to date are conﬂicting [13, 22–25]. We found a
signiﬁcant effect of one topical decolonisation therapy dur-
ing the patient’s ﬁrst MRSA-positive hospital stay even
though we could not control the adherence to the decoloni-
sationprotocol(datanotshownindetail).However,wewere
unable to conﬁrm a clearly signiﬁcant effect of one initial
topical decolonisation therapy over the long term (consid-
ering only patients being re-admitted at least once) as
described by Marschall et al. [13]. As we categorised all
patients who did not fulﬁl our ‘‘MRSA-negative’’ require-
ments as ‘‘MRSA-positive’’ to exclude a possible overesti-
mation of any effect, we can not exclude the possibility that
we underestimated the possible effect of a decolonisation
therapy in our cohort. Thus, based on our results, the effec-
tiveness of topical decolonisation therapy remains an unre-
solved question, even though recent publications report a
signiﬁcant advantage if the decolonisation treatments are
rigorously controlled and a systemic therapy is partially
added [22].
As the risk of infection seems to depend on the initially
colonised anatomical site, it has also been suspected that
Table 2 Multivariate analysis of MRSA loss according to age group, decolonisation therapy at ﬁrst hospital stay, and MRSA colonisation at
different anatomical sites
Variables Patients re-admitted at least once p value
HR of
MRSA loss
95% CI
for HR
Age at ﬁrst hospital stay (years)
([65/B65 years)
0.87 0.57–1.33 0.53
Topical decolonisation therapy initiated during the
ﬁrst hospital stay: Yes/no
0.75 0.51–1.11 0.15
Anatomical site (total) – – \0.01
Only wounds/only nares 1.63 0.69–3.86 0.26
Nares and other anatomical sites but no wounds/only nares 0.49 0.28–0.88 0.02
Throat, mouth, tracheal secretion, bronchial secretion or BAL
without nares/only nares
0.65 0.33–1.28 0.22
Nares and other anatomical sites including wounds/only nares 0.34 0.19–0.63 \0.01
Other anatomical sites including urinary tract and ano-genital
region without nares and without wounds/only nares
0.47 0.21–1.06 0.07
Wounds and other anatomical sites without nares/only nares 0.83 0.41–1.67 0.59
Any other anatomical sites or combinations/only nares 0.76 0.35–1.66 0.49
Unknown/only nares 3.44 0.45–26.39 0.24
HR Hazard ratio, CI conﬁdence interval
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Long-term persistence of MRSA in re-admitted patients 369the loss of MRSA depends on the kind of anatomical sites
initially colonised [20]. We therefore calculated the risks
according to several anatomical site categories and found
that the loss or persistence differed signiﬁcantly. In
addition, MRSA persistence was prolonged if more than
one anatomical site tested positive, which is consistent to
the ﬁndings reported by Buehlmann et al. [22]. Our data
suggest starting decolonisation therapy as early as possi-
ble after MRSA has been detected and to focus on
patients who are colonised at only one or few different
body sites.
Unfortunately our data are limited by a certain incom-
pleteness of microbiological follow-up due to the obser-
vational nature of our study with no deﬁned interval
screening protocol for MRSA. Hence, we cannot exclude
the possibility that patients colonised at various anatomical
sites were only detected due to an increased severity of
illness or that patients found colonised at only few ana-
tomical sites were biased by missing screening cultures of
additional anatomical body sites.
Only a few published studies have addressed the ques-
tion of MRSA persistence over the long term, and all of
these studies differ in methodolgy and study design (see
Table 3)[ 13–15, 26].
Most studies carried out to date, including our study, are
limited by the fact that there is no information on the
MRSA status of patients between different admissions.
This leads to the problem of interval censoring, which we
could not solve. This problem requires further studies that
include data from ambulatory patient care.
Conclusions
A high percentage—about 40%—of all MRSA-positive
patients was re-admitted at least once. At least 15% of all
patients lost MRSA colonisation over time. The HLT of
MRSA in our selected patient cohort appears to be pro-
longed, with a HLT of about 560 days. Multiple-site car-
riage seems to determine a prolonged carriage of MRSA.
The shortest MRSA persistence times were found in
patients who were only colonised in wounds.
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